Precision Cancer Medicine Registration Study of Omics Data from Genomic Information Analysis Leading to New Effective Therapy

Precision Cancer Medicine Registration Study of Omics Data from Genomic Information Analysis Leading to New Effective Therapy - PROFILE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028439

Enrollment

500

Registered

2017-10-01

Start date

2017-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

a) any cancer that becomes refractory/intolerant to standard therapy b) cancer of unknown primary c) rare malignancy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) any cancer or malignancy that becomes refractory/intolerant to standard thearpy b) cancer of unknown origin c) rare cancer

Exclusion criteria

Exclusion criteria: - those who cannot consent

Design outcomes

Primary

Measure	Time frame
The following items will be recorded in the registry. a. Demographic (age, sex, co-morbidities, family history, social history) b. Diagnosis (tumor type, histology, primary site, metastatic site, stage) c. Treatment (modality, regimen, response, duration of response, adverse event, QOL) d. Genomic alteration (method, QC, gene name, alteration type, details of alteration etc.) e. Outcome (overall survival, disease-free survival, progression-free survival, relapse-free survival etc.)	—

Measure

Time frame

The following items will be recorded in the registry. a. Demographic (age, sex, co-morbidities, family history, social history) b. Diagnosis (tumor type, histology, primary site, metastatic site, stage) c. Treatment (modality, regimen, response, duration of response, adverse event, QOL) d. Genomic alteration (method, QC, gene name, alteration type, details of alteration etc.) e. Outcome (overall survival, disease-free survival, progression-free survival, relapse-free survival etc.)

—

Countries

Japan

Contacts

Public ContactJunko Yokobori

Tokyo Medical and Dental University Cancer Center

j.yokobori.mnrs@tmd.ac.jp03-5803-4873

Outcome results